Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vacarro, Glaucia Dos Santos
NCT05143177: A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease with Mild to Moderate Aortic Stenosis (EVOID-AS)	Active, not recruiting	2/3	867	Canada, US	Evogliptin, DA-1229, Placebo	REDNVIA Co., Ltd.	Calcific Aortic Valve Disease	05/26	12/26
Baxter, Jennifer
NCT05143177: A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease with Mild to Moderate Aortic Stenosis (EVOID-AS)	Active, not recruiting	2/3	867	Canada, US	Evogliptin, DA-1229, Placebo	REDNVIA Co., Ltd.	Calcific Aortic Valve Disease	05/26	12/26
COSIRA-II, NCT05102019: Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II	Recruiting	N/A	380	Canada, US	Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry	Neovasc Inc., Shockwave Medical, Inc.	Refractory Angina	06/25	12/28